| Income statement (USD) | Q2 2026 ended Jun 30, 2026 | Q1 2026 ended Mar 31, 2026 | Q4 2025 ended Dec 31, 2025 | Q3 2025 ended Sep 30, 2025 | Q2 2025 ended Jun 30, 2025 | Q1 2025 ended Mar 31, 2025 | Q4 2024 ended Dec 31, 2024 | Q3 2024 ended Sep 30, 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 16.61B | 16.29B | 16.40B | 17.28B | 15.81B | 15.53B | 15.62B | 16.66B |
| Cost of revenue | 4.39B | 4.20B | 5.55B | 3.85B | 3.56B | 3.42B | 3.83B | 4.08B |
| Gross profit | 12.21B | 12.09B | 10.85B | 13.42B | 12.25B | 12.11B | 11.80B | 12.58B |
| Research and development | 9.74B | 12.59B | 3.89B | 4.23B | 4.05B | 3.62B | 4.58B | 5.86B |
| Selling, general and admin | 2.90B | 2.70B | 2.90B | 2.63B | 2.65B | 2.55B | 2.86B | 2.73B |
| Interest expense | 525.00M | 479.00M | 411.00M | 327.00M | 305.00M | 313.00M | 328.00M | 330.00M |
| Income before tax | -683.00M | -3.53B | 3.42B | 6.75B | 5.00B | 5.90B | 4.17B | 4.09B |
| Income tax | 654.00M | 709.00M | 458.00M | 958.00M | 571.00M | 818.00M | 426.00M | 929.00M |
| Net income | -1.33B | -4.24B | 2.96B | 5.79B | 4.43B | 5.08B | 3.74B | 3.16B |
| EPS | -0.54 | -1.72 | 1.21 | 2.32 | 1.76 | 2.01 | 1.48 | 1.25 |
| EPS (diluted) | -0.54 | -1.72 | 1.20 | 2.32 | 1.76 | 2.01 | 1.48 | 1.24 |
| Diluted shares | 2.47B | 2.47B | -7.00M | 2.50B | 2.51B | 2.53B | -2.00M | 2.54B |
| Dividends per share | 0.85 | 0.85 | 0.85 | 0.81 | 0.81 | 0.81 | 0.81 | 0.77 |
From Merck's 10-K and 10-Q filings with the SEC. Fourth quarters, and quarters where the company only reported year-to-date totals, are worked out by subtracting the earlier quarters. Fiscal years are the company's own, so they may not match the calendar. A blank cell means the company did not report that line. New to this? Read income statement or reading a 10-K.
Revenue, earnings, margins and balance sheet trends drawn by TradingView from its own data, so figures can differ slightly from the SEC table above.